UK-447841

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H30ClNO4
Molecular Weight	395.92
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COCC[C@H](CC1(CCCC1)C(=O)NCCCC2=CC=C(Cl)C=C2)C(O)=O

InChI

InChIKey=UOGBJRPKRSUJRU-QGZVFWFLSA-N

InChI=1S/C21H30ClNO4/c1-27-14-10-17(19(24)25)15-21(11-2-3-12-21)20(26)23-13-4-5-16-6-8-18(22)9-7-16/h6-9,17H,2-5,10-15H2,1H3,(H,23,26)(H,24,25)/t17-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H30ClNO4
Molecular Weight	395.92
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 11:18:26 GMT 2023` Edited by `admin` on `Sat Dec 16 11:18:26 GMT 2023`
Record UNII	T76DLY464G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

UK-447841

Code

English

(2S)-2-((1-(3-(4-CHLOROPHENYL)PROPYLCARBAMOYL)CYCLOPENTYL)METHYL)-4-METHOXY-BUTANOIC ACID

Systematic Name

English

UK447841

Code

English

(.ALPHA.S)-1-(((3-(4-CHLOROPHENYL)PROPYL)AMINO)CARBONYL)-.ALPHA.-(2-METHOXYETHYL)CYCLOPENTANEPROPANOIC ACID

Systematic Name

English

CYCLOPENTANEPROPANOIC ACID, 1-(((3-(4-CHLOROPHENYL)PROPYL)AMINO)CARBONYL)-.ALPHA.-(2-METHOXYETHYL)-, (.ALPHA.S)-

Systematic Name

English

(S)-2-((1-((3-(4-CHLOROPHENYL)PROPYL)CARBAMOYL)CYCLOPENTYL)METHYL)-4-METHOXYBUTANOIC ACID

Systematic Name

English

Code System Code Type Description

PUBCHEM

15978653

Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023

PRIMARY

FDA UNII

T76DLY464G

Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023

PRIMARY

CAS

465528-01-2

Created by admin on Sat Dec 16 11:18:26 GMT 2023 , Edited by admin on Sat Dec 16 11:18:26 GMT 2023

PRIMARY

Related Record Type Details


					T76DLY464G

UK-447841

ACTIVE MOIETY

Comments:

Mechanism of Action: Neprilysin inhibitor; Highest Development Phase: Discontinued for Female sexual dysfunction; Most Recent Events: 01 Jan 2008 Discontinued - Phase-II for Female sexual dysfunction in Sweden (PO), 02 Aug 2004 Phase-II clinical trials in Female sexual dysfunction in Sweden (PO)


					T76DLY464G

UK-447841

ACTIVE MOIETY

Comments:

In one embodiment, the invention pertains to method of the invention wherein the NEP inhibitor is UK-447841 , or a compound of the PCT application WO 2002/079143, which is herein incorporated by reference, or a pharmaceutically acceptable salt thereof. UK- 447841 is an NEP inhibitor of the following formula.(synthesis of the structure given)